Melanoma genetics and therapeutic approaches in the 21st century: Moving from the benchside to the bedside

Journal of Investigative Dermatology

Volumn 128, Issue 11, 2008, Pages 2575-2595

  Hocker, Thomas L ^a   Singh, Meena K ^a   Tsao, Hensin ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 5 AZA 2' DEOXYCYTIDINE; 5,6 DIHYDROAZACITIDINE; ANTHRAX LETHAL TOXIN; ANTISENSE OLIGONUCLEOTIDE; BACTERIAL TOXIN; BORTEZOMIB; CARBOPLATIN; CHIR 265; CISPLATIN; DACARBAZINE; DOCETAXEL; EVEROLIMUS; FAZARABINE; GOSSYPOL; IMATINIB; ISIS 2503; LONAFARNIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OBATOCLAX; OBLIMERSEN; PACLITAXEL; PLX 4032; PROTEIN NOXA; SORAFENIB; STEM CELL FACTOR; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER GENETICS; CANCER SURVIVAL; CELL SURVIVAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GENE LOCUS; GENE MUTATION; HUMAN; MELANOMA; METASTASIS; MONOTHERAPY; NEUTROPENIA; ONCOGENE; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 53949103143     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2008.226     Document Type: Note

References (205)

1. Ackermann J, Frutschi M, Kaloulis K, McKee T, Trumpp A, Beermann F (2005) Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res 65:4005-11
2. Ahmad T, Marais R, Pyle L, James M, Schwartz B, Gore M et al. (2004) BAY 43-9006 in patients with advanced melanoma: the Royal Marsden experience. J Clin Oncol 22:7506
3. Alao JP (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6:24
4. Albino AP, Le Strange R, Oliff AI, Furth ME, Old LJ (1984) Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature 308:69-72
5. Amaravadi RK, Schuchter LM, Kramer A, Barth SF, Villanueva J, Troxel AB et al. (2006) Preliminary results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. J Clin Oncol 24:8009
6. Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A (2004) Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 64:4912-8
7. Arriola EL, Rodriguez-Lopez AM, Hickman JA, Chresta CM (1999) Bcl-2 overexpression results in reciprocal downregulation of Bcl-X(L) and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis. Oncogene 18:1457-64
8. Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281:1305-1308
9. Aziz SA, Pick-Golan E, McCarthy MM, Flaherty KT, Camp RL, Rimm DL et al. (2007) 2007 ASCO annual meeting proceedings Part I. J Clin Oncol 25:8521
10. Bae SI, Cheriyath V, Jacobs BS, Reu FJ, Borden EC (2008) Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene 27:490-8
11. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL et al. (1985) Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41:899-906
12. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-48
13. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y et al. (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152-61
14. Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L (2001) Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol 21:2144-53
15. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J et al. (1996) The p16-cyclin D/ Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56:5475-83
16. Bastian BC, Kashani-Sabet M, Hamm H, Godfrey T, Moore DH II, Brocker EB et al. (2000a) Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 60:1968-73
17. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D (1998) Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58:2170-5
18. Bastian BC, LeBoit PE, Pinkel D (2000b) Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol 157:967-72
19. Bauer J, Curtin JA, Pinkel D, Bastian BC (2007) Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 127:179-82
20. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U et al. (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24:4738-45
21. Bennett DC (2003) Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22:3063-9
22. Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16:6-21
23. Blaheta RA, Nau H, Michaelis M, Cinatl J Jr (2002) Valproate and valproate-analogues: potent tools to fight against cancer. Curr Med Chem 9:1417-33
24. Boogerd W, de Gast GC, Dalesio O (2007) Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? Cancer 109:306-12
25. Borner C, Schlagbauer Wadl H, Fellay I, Selzer E, Polterauer P, Jansen B (1999) Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice. Melanoma Res 9:347-50
26. Boyle GM, Martyn AC, Parsons PG (2005) Histone deacetylase inhibitors and malignant melanoma. Pigment Cell Res 18:160-6
27. Carreira S, Goodall J, Aksan I, La Rocca SA, Galibert MD, Denat L et al. (2005) Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433:764-9
28. Carreira S, Liu B, Goding CR (2000) The gene encoding the T-box factor Tbx2 is a target for the microphthalmia-associated transcription factor in melanocytes. J Biol Chem 275:21920-7
29. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436:725-30
30. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T et al. (2001) BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8:705-711
31. Chetoui N, Sylla K, Gagnon-Houde JV, Alcaide-Loridan C, Charron D, Al-Daccak R et al. (2008) Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res 6:42-52
32. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C et al. (1997) Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 11:2822-34
33. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N et al. (1999) Essential role for oncogenic Ras in tumour maintenance. Nature 400:468-72
34. Collisson EA, De A, Suzuki H, Gambhir SS, Kolodney MS (2003) Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 63:5669-73
35. Cowan JM, Halaban R, Francke U (1988) Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. J Natl Cancer Inst 80:1159-64
36. Cuconati A, Mukherjee C, Perez D, White E (2003) DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev 17:2922-32
37. Curtin JA, Busam K, Pinkel D, Bastian BC (2006a) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-4346
38. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al. (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-47
39. Curtin JA, Stark MS, Pinkel D, Hayward NK, Bastian BC (2006b) PI3-kinase subunits are infrequent somatic targets in melanoma. J Invest Dermatol 126:1660-3
40. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J et al. (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61:3535-40
41. da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R (2005) Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 65:10686-91
42. Dancey JE (2006) Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 5:1065-73
43. Danial NN, Korsmeyer SJ (2004) Cell death: critical control points. Cell 116:205-19
44. Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J et al. (2003) Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 21:2551-7
45. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54
46. Del Bufalo D, Trisciuoglio D, Scarsella M, Zangemeister-Wittke U, Zupi G (2003) Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene 22:8441-7
47. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278:687-9
48. Delmas V, Beermann F, Martinozzi S, Carreira S, Ackermann J, Kumasaka M et al. (2007) Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 21:2923-35
49. Dhawan P, Singh AB, Ellis DL, Richmond A (2002) Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 62:7335-42
50. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z et al. (2003) BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 63:3883-5
51. Dorsky RI, Moon RT, Raible DW (1998) Control of neural crest cell fate by the Wnt signalling pathway. Nature 396:370-3
52. Dorval T, Negrier S, Chevreau C, Avril MF, Baume D, Cupissol D et al. (1999) Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Cancer 85:1060-6
53. Eigentler TK, Caroli UM, Radny P, Garbe C (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4:748-59
54. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R et al. (2006) Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95:581-6
55. Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo HM (2003) Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res 63:8330-7
56. Ewing J (1930) The Problems of Melanoma. B J Med 11:852-6
57. Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari AW Jr et al. (2005) Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 65:6294-304
58. Filmus J, Robles AI, Shi W, Wong MJ, Colombo LL, Conti CJ (1994) Induction of cyclin D1 overexpression by activated ras. Oncogene 9:3627-33
59. Flaherty KT, Brose M, Schuchter L, Tuveson D, Lee R, Schwartz B et al. (2004) Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. Proceedings from the American Society of Clinical Oncology. New Orleans, LA, 2004. pp. 708: Abstract #7507
60. Flaherty KT, Brose M, Shchucter L, Tuveson D, Lee R, Schwartz C et al. (2004) Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. Journal of Clinical Oncology. ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 7507
61. Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, Titus-Ernstoff L et al. (1992) Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 89:10557-61
62. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M et al. (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65:4320-33
63. Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G, Debatin KM (2001) Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene 20:1063-75
64. Galluzzi L, Larochette N, Zamzami N, Kroemer G (2006) Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 25:4812-30
65. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-22
66. Gautschi O, Tschopp S, Olie RA, Leech SH, Simoes-Wust AP, Ziegler A et al. (2001) Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 93:463-71
67. Giebel LB, Spritz RA (1991) Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. Proc Natl Acad Sci USA 88:8696-9
68. Gogas HJ, Kirkwood JM, Sondak VK (2007) Chemotherapy for metastatic melanoma: time for a change? Cancer 109:455-64
69. Gollob JA, Sciambi CJ, Peterson BL, Richmond T, Thoreson M, Moran K et al. (2006) Phase I trial of sequential low-dose 5-aza-2′- deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 12:4619-27
70. Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, Nickoloff BJ et al. (2007) Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 117:719-29
71. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445:851-7
72. Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D et al. (2006) V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 103:57-62
73. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-78
74. Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4:361-70
75. Ha L, Ichikawa T, Anver M, Dickins R, Lowe S, Sharpless NE et al. (2007) ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci USA 104:10968-73
76. Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL et al. (2008) The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 14:230-9
77. Han Z, Chatterjee D, Early J, Pantazis P, Hendrickson EA, Wyche JH (1996) Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL. Cancer Res 56:1621-8
78. Heere-Ress E, Thallinger C, Lucas T, Schlagbauer-Wadl H, Wacheck V, Monia BP et al. (2002) Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int J Cancer 99:29-34
79. Helmbach H, Rossmann E, Kern MA, Schadendorf D (2001) Drug-resistance in human melanoma. Int J Cancer 93:617-22
80. Henry H, Thomas A, Shen Y, White E (2002) Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death. Oncogene 21:748-60
81. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-54
82. Hersey P, Zhuang L, Zhang XD (2006) Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model. Int Rev Cytol 251:131-58
83. Hocker T, Tsao H (2007) Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 28:578-88
84. Hodgkinson CA, Moore KJ, Nakayama A, Steingrimsson E, Copeland NG, Jenkins NA et al. (1993) Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 74:395-404
85. Huang S, Luca M, Gutman M, McConkey DJ, Langley KE, Lyman SD et al. (1996) Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 13:2339-47
86. Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2:277-88
87. Ilmonen S, Hernberg M, Pyrhonen S, Tarkkanen J, Asko-Seljavaara S (2005) Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma. Melanoma Res 15:375-81
88. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M et al. (1998) bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4:232-4
89. Jansen B, Schlagbauer-Wadl H, Eichler HG, Wolff K, van Elsas A, Schrier PI et al. (1997) Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis. Cancer Res 57:362-5
90. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T et al. (2000) Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356:1728-33
91. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96
92. Jiang CC, Chen LH, Gillespie S, Wang YF, Kiejda KA, Zhang XD et al. (2007) Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis. Cancer Res 67:9750-61
93. Jiveskog S, Ragnarsson-Olding B, Platz A, Ringborg U (1998) N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Invest Dermatol 111:757-61
94. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-40
95. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95:8292-7
96. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F et al. (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23:6292-8
97. Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S et al. (2005) AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 10:975-87
98. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B et al. (2006) Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125:1269-1281
99. Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Woude GF (2002) Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci USA 99:3052-7
100. Kulaeva OI, Draghici S, Tang L, Kraniak JM, Land SJ, Tainsky MA (2003) Epigenetic silencing of multiple interferon pathway genes after cellular immortalization. Oncogene 22:4118-27
101. Kumar CC, Diao R, Yin Z, Liu Y, Samatar AA, Madison V et al. (2001) Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling. Biochim Biophys Acta 1526:257-68
102. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S et al. (2003) BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 9:3362-8
103. Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P et al. (2006) MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313:521-2
104. Lassam N, Bickford S (1992) Loss of c-kit expression in cultured melanoma cells. Oncogene 7:51-6
105. Leiter U, Schmid RM, Kaskel P, Peter RU, Krahn G (2000) Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res 292:225-32
106. Li G, Bush JA, Ho VC (2000) p53-dependent apoptosis in melanoma cells after treatment with camptothecin. J Invest Dermatol 114:514-9
107. Li G, Tang L, Zhou X, Tron V, Ho V (1998) Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res 8:17-23
108. Libra M, Malaponte G, Navolanic PM, Gangemi P, Bevelacqua V, Proietti L et al. (2005) Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle 4:1382-4
109. Lorigan P, Corrie P, Chao D, Nathan P, Ahmad T, Marais R et al. (2006) Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients. J Clin Oncol 24:8012
110. Lorusso P, Krishnamurthi S, Rinehart JR, Nabell L, Croghan G, Varterasian M et al. (2005a) 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 23:3011
111. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY et al. (2005b) Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23:5281-93
112. Madhunapantula SV, Sharma A, Robertson GP (2007) PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res 67:3626-36
113. Maelandsmo GM, Florenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R et al. (1996) Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Br J Cancer 73:909-16
114. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129:1261-74
115. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J et al. (2005) CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104:1045-8
116. Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W et al. (2005) A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103:2584-9
117. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263-84
118. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK et al. (2002) Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109:707-718
119. Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K et al. (2005) The RAS/RAF/ MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 10:2986-3001
120. Mhaidat NM, Zhang XD, Jiang CC, Hersey P (2007) Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res 13:1308-14
121. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM et al. (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720-4 s
122. Miyake H, Hara I, Gohji K, Yamanaka K, Arakawa S, Kamidono S (1998) Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer. Anticancer Res 18:3087-92
123. Molhoek KR, Brautigan DL, Slingluff CL Jr (2005) Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor rapamycin. J Transl Med 3:39
124. Montone KT, van Belle P, Elenitsas R, Elder DE (1997) Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 10:939-44
125. Mooi WJ, Peeper DS (2006) Oncogene-induced cell senescence - halting on the road to cancer. N Engl J Med 355:1037-46
126. Morgillo F, Lee HY (2006) Lonafarnib in cancer therapy. Expert Opin Investig Drugs 15:709-19
127. Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS et al. (1996) X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381:335-41
128. Mustika R, Budiyanto A, Nishigori C, Ichihashi M, Ueda M (2005) Decreased expression of Apaf-1 with progression of melanoma. Pigment Cell Res 18:59-62
129. Natali PG, Nicotra MR, Winkler AB, Cavaliere R, Bigotti A, Ullrich A (1992) Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 52:197-201
130. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR et al. (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 104:19512-19517
131. Nickoloff BJ, Hendrix MJ, Pollock PM, Trent JM, Miele L, Qin JZ (2005) Notch and NOXA-related pathways in melanoma cells. J Investig Dermatol Symp Proc 10:95-104
132. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F et al. (2003) Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 17:1475-86
133. Nikiforov MA, Riblett M, Tang WH, Gratchouck V, Zhuang D, Fernandez Y et al. (2007) Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci USA 104:19488-93
134. Nishimura EK, Granter SR, Fisher DE (2005) Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science 307:720-4
135. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-81
136. Omholt K, Platz A, Ringborg U, Hansson J (2001) Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma. Int J Cancer 92:839-42
137. Panka DJ, Cho DC, Atkins MB, Mier JW (2008) GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem 283:726-32
138. Papp T, Pemsel H, Zimmermann R, Bastrop R, Weiss DG, Schiffmann D (1999) Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J Med Genet 36:610-4
139. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD et al. (2005) BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 15:249-54
140. Petti C, Molla A, Vegetti C, Ferrone S, Anichini A, Sensi M (2006) Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res 66:6503-11
141. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM et al. (2003) High frequency of BRAF mutations in nevi. Nat Genet 33:19-20
142. Qin JZ, Xin H, Sitailo LA, Denning MF, Nickoloff BJ (2006) Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res 66:9636-45
143. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V et al. (2005) Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65:6282-93
144. Rao RD, Windschitl HE, Allred JB, Lowe VJ, Maples WJ, Gornet MK et al. (2006) Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 24:8043
145. Reiner SL (2005) Epigenetic control in the immune response. Hum Mol Genet 14 Spec No 1 R41-6
146. Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N et al. (2006) Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol 24:3771-9
147. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER (1999) Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 154:325-9
148. Roskoski R Jr (2005) Structure and regulation of Kit protein-tyrosine kinase - the stem cell factor receptor. Biochem Biophys Res Commun 338:1307-15
149. Rothhammer T, Bosserhoff AK (2007) Epigenetic events in malignant melanoma. Pigment Cell Res 20:92-111
150. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P (1997) Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275:1790-2
151. Sauter ER, Yeo UC, von Stemm A, Zhu W, Litwin S, Tichansky DS et al. (2002) Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 62:3200-6
152. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ et al. (1998) Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17:1675-87
153. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M et al. (2008) Identification of cells initiating human melanomas. Nature 451:345-9
154. Schmitt CA, Rosenthal CT, Lowe SW (2000) Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 6:1029-35
155. Selzer E, Schlagbauer-Wadl H, Okamoto I, Pehamberger H, Potter R, Jansen B (1998) Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res 8:197-203
156. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593-602
157. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP (2005) Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65:2412-21
158. Sharpless NE, Kannan K, Xu J, Bosenberg MW, Chin L (2003) Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene 22:5055-9
159. Slipicevic A, Holm R, Nguyen MT, Bohler PJ, Davidson B, Florenes VA (2005) Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am J Clin Pathol 124:528-36
160. Smalley KS, Eisen TG (2003) Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer 105:165-75
161. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5:1136-44
162. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X et al. (2001) Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409:207-11
163. Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22:3138-51
164. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-62
165. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A et al. (1998) Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 7:209-16
166. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW et al. (2004) Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64:7002-10
167. Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V et al. (2007) Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/ AKT pathways. Proc Natl Acad Sci USA 104:5895-900
168. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-62
169. Straume O, Smeds J, Kumar R, Hemminki K, Akslen LA (2002) Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol 161:229-37
170. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E et al. (2001) Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7:1419-28
171. Tang L, Tron VA, Reed JC, Mah KJ, Krajewska M, Li G et al. (1998) Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 4:1865-71
172. Tassabehji M, Newton VE, Read AP (1994) Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (MITF) gene. Nat Genet 8:251-5
173. Thallinger C, Wolschek MF, Wacheck V, Maierhofer H, Gunsberg P, Polterauer P et al. (2003) Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol 120:1081-6
174. Thomas NE, Berwick M, Cordeiro-Stone M (2006) Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation? J Invest Dermatol 126:1693-6
175. Thornberry NA, Lazebnik Y (1998) Caspases: enemies within. Science 281:1312-6
176. Tron VA, Krajewski S, Klein-Parker H, Li G, Ho VC, Reed JC (1995) Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am J Pathol 146:643-50
177. Tsao H, Atkins MB, Sober AJ (2004a) Management of cutaneous melanoma. N Engl J Med 351:998-1012
178. Tsao H, Benoit E, Sober AJ, Thiele C, Haluska FG (1998a) Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res 58:109-13
179. Tsao H, Goel V, Wu H, Yang G, Haluska FG (2004b) Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122:337-41
180. Tsao H, Zhang X, Benoit E, Haluska FG (1998b) Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16:3397-402
181. Tsao H, Zhang X, Fowlkes K, Haluska FG (2000) Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 60:1800-4
182. Valentini A, Gravina P, Federici G, Bernardini S (2007) Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol Ther 6:185-91
183. van den Oord JJ, Vandeghinste N, De Ley M, De Wolf-Peeters C (1994) Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 145:294-300
184. Vaux DL, Cory S, Adams JM (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-2
185. Verhaegen M, Bauer JA, Martin de la Vega C, Wang G, Wolter KG, Brenner JC et al. (2006) A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 66:11348-59
186. Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID, Fountain JW (1998) Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 22:157-63
187. Wang YF, Jiang CC, Kiejda KA, Gillespie S, Zhang XD, Hersey P (2007) Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res 13:4934-42
188. Widlund HR, Fisher DE (2003) Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene 22:3035-41
189. Widlund HR, Horstmann MA, Price ER, Cui J, Lessnick SL, Wu M et al. (2002) Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol 158:1079-87
190. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. (2005) Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19:1294-305
191. Willmore-Payne C, Holden JA, Hirschowitz S, Layfield LJ (2006) BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol 37:520-7
192. Willmore-Payne C, Holden JA, Tripp S, Layfield LJ (2005) Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 36:486-93
193. Wolter KG, Verhaegen M, Fernandez Y, Nikolovska-Coleska Z, Riblett M, de la Vega CM et al. (2007) Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ 14:1605-16
194. Wu M, Hemesath TJ, Takemoto CM, Horstmann MA, Wells AG, Price ER et al. (2000) c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev 14:301-12
195. Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F et al. (2006) Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106:2005-11
196. Yamada KM, Araki M (2001) Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 114:2375-82
197. Yazdi AS, Palmedo G, Flaig MJ, Puchta U, Reckwerth A, Rutten A et al. (2003) Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 121:1160-2
198. Yu Q, Geng Y, Sicinski P (2001) Specific protection against breast cancers by cyclin D1 ablation. Nature 411:1017-21
199. Zakut R, Perlis R, Eliyahu S, Yarden Y, Givol D, Lyman SD et al. (1993) KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene 8:2221-9
200. Zhai D, Jin C, Huang Z, Satterthwait AC, Reed JC (2008) Differential regulation of Bax and Bak by anti-apoptotic Bcl-2-family proteins, Bcl-B and Mcl-1. J Biol Chem 283:9580-6
201. Zhai S, Yaar M, Doyle SM, Gilchrest BA (1996) Nerve growth factor rescues pigment cells from ultraviolet-induced apoptosis by upregulating BCL-2 levels. Exp Cell Res 224:335-43
202. Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P (2003) Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 22:2869-81
203. Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-34
204. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C (2000) Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157:1123-8
205. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ et al. (1996) Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97-9